Adaptation to extreme stress: Post-traumatic stress disorder, neuropeptide Y and metabolic syndrome

Experimental Biology and Medicine

Volumn 235, Issue 10, 2010, Pages 1150-1162

  Rasmusson, Ann M ^a,b,c   Schnurr, Paula P ^d,e   Zukowska, Zofia ^f   Scioli, Erica ^a,b,c   Forman, Daniel E ^a,g  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b NATIONAL CENTER FOR PTSD   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CENTER FOR PTSD   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allopregnanolone; Cortisol; Dehydroepiandrosterone; Depression; Metabolic syndrome; Neuropeptide Y; Neurosteroids; Obesity hypertension; Post traumatic stress disorder; Testosterone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID; CORTICOTROPIN; ELTANOLONE; GLUCOCORTICOID; HYDROCORTISONE; MIFEPRISTONE; NEUROPEPTIDE Y; NORADRENALIN; PLACEBO; PRASTERONE; TESTOSTERONE; YOHIMBINE;

BLOOD PRESSURE; BODY MASS; CALORIC INTAKE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG USE; DYSLIPIDEMIA; ENERGY EXPENDITURE; EPIGENETICS; FAT INTAKE; GENETIC ASSOCIATION; HORMONE RESPONSE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID DIET; LOW DRUG DOSE; MENTAL DISEASE; MENTAL HEALTH; MENTAL STRESS; METABOLIC REGULATION; METABOLIC SYNDROME X; NEUROTRANSMITTER RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORADRENALIN RELEASE; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUGAR INTAKE; TESTOSTERONE SYNTHESIS; UNITED STATES; WAIST CIRCUMFERENCE; ADAPTATION; ANIMAL; BIOLOGICAL MODEL; COMPLICATION; FEMALE; GENETICS; MALE; MOUSE; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; DEHYDROEPIANDROSTERONE; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; MALE; METABOLIC SYNDROME X; MICE; MODELS, BIOLOGICAL; NEUROPEPTIDE Y; PREGNANOLONE; RISK FACTORS; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PHYSIOLOGICAL; TESTOSTERONE;

ANIMALIA; MUS;

EID: 77957843240     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2010.009334     Document Type: Conference Paper

References (161)

1. Heppner PS, Crawford EF, Haji UA, Afari N, Hauger RL, Dashevsky BA, Horn PS, Nunnick SE, Baker DG. The association of posttraumatic stress disorder and metabolic syndrome: a study of increased health risk in Veterans. BMC Med 2009;7. See: http://www.biomedcentral.com/1741-7015/7/1 (last checked 22 July 2010)
2. Weathers FW, Keane TM, Davidson JRT. Clinician-administered PTSD Scale: a review of the first ten years of research. Depress Anxiety 2001;13:132-56
3. Violanti JM, Fekedulegn D, Hartley TA, Andrew ME, Charles LE, Mnatsakanova A, Burchfiel CM. Police trauma and cardiovascular disease: association between PTSD symptoms and metabolic syndrome. Int J Emerg Mental Health 2006;8:227-37
4. Breslau N, Davis GC, Peterson EL, Schultz LR. A second look at comorbidity in victims of trauma: the posttraumatic stress disorder-major depression connection. Biol Psychiatry 2000;48:902-9
5. Glover DA, Stuber M, Polan RE. Allostatic load in women with and without PTSD symptoms. Psychiatry 2006;69:191-203 (Pubitemid 44706197)
6. McEwen BS, Wingfield JC. What is in a name? Integrating homeostasis, allostasis and stress. Hormones Behav 2010;57:105-11
7. Schnurr PP, Green BL. Trauma and Health: Physical Health Consequences of Exposure to Extreme Stress. Washington, DC: American Psychological Association, 2004
8. Schnurr PP, Jankowski MK. Physical health and post-traumatic stress disorder: review and synthesis. Sem Clin Neuropsychiatry 1999;4:295-304
9. Das SR, Kinsinger LS, Yancy WS Jr, Wang A, Ciesco E, Burdick M, Yevich SJ. Obesity prevalence among veterans at Veterans Affairs medical facilities. Am J Prev Med 2005;28:291-4 (Pubitemid 40576236)
10. Vieweg WVR, Bates JDA, Quinn III, Fernandez A, Hasnain N, Pandurangi A. Posttraumatic stress disorder as a risk factor for obesity in male military veterans. Acta Psychiatr Scand 2007;116:483-7 (Pubitemid 350086146)
11. Cwikel J, Abdelgani A, Goldsmith JR, Quastel M, Yevelson II. Two-year follow-up study of stress-related disorders among immigrants to Israel from the Chernobyl area. Environ Health Perspect 1997;105(Suppl. 6):1545-50
12. Davidson JRT, Hughes DC, Blazer DG, George LK. Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med 1991;21:713-21
13. Kibler JL, Joshi K, Ma M. Hypertension in relation to posttraumatic stress disorder in the US National Comorbidity Survey. Behav Med 2008;34:125-31
14. O'Toole BI, Catts SV. Trauma, PTSD, and physical health: an epidemiological study of Australian Vietnam veterans. J Psychosom Res 2008;64:33-40
15. Sawchuk CN, Roy-Byrne PP, Goldberg J, Manson SM, Noonan C, Beals J, Buchwald DS. The relationship between post-traumatic stress disorder, depression and cardiovascular disease in an American Indian tribe. Psychol Med 2005;35:1785-94
16. Emdad R, Söndergaard HP, Agartz I, Theorell T. Cardiovascular reactivity in posttraumatic stress disorder (PTSD) patients undergoing magnetic resonance imaging (MRI). Stress Trauma Crisis 2004;7:243-55
17. Kang HK, Bullman TA, Taylor JW. Risk of selected cardiovascular diseases and posttraumatic stress disorder among former World War II prisoners of war. AEP 2006;16:381-6
18. Santic Z, Lukic A, Sesar D, Milicevic S, Ilakovac V. Long-term follow-up of blood pressure in family members of soldiers killed during the war in Bosnia and Herzegovina. Croat Med J 2006;47:416-23
19. Schnurr PP, Spiro A III, Paris AH. Physician-diagnosed medical disorders in relation to PTSD symptoms in older male military Veterans. Health Psychol 2000;19:91-7
20. Granada NS, Smith TC, Swanson GM, Harris RB, Shahar E, Smith B, Boyko EJ, Wells TS, Ryan MA. Newly reported hypertension after military combat deployment in a large population-based study. Hypertension 2009;54:966-73
21. Andersen J, Wade M, Possemato K, Ouimette P. Association between posttraumatic stress disorder and primary care provider-diagnosed disease among Iraq and Afghanistan veterans. Psychosomatic Med 2010;72:498-504
22. Pole N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychol Bull 2007;133:725-46
23. Buckley TC, Kaloupek DG. A meta-analytic examination of basal cardiovascular activity in posttraumatic stress disorder. Psychosom Med 2001;63:585-94
24. Beckham JC, Feldman ME, Barefoot JC, Fairbank JA, Helms MJ, Haney TL, Hertzberg MA, Moore SD, Davidson JR. Ambulatory cardiovascular activity in Vietnam combat Veterans with and without posttraumatic stress disorder. J Consult Clin Psychol 2000;68:269-76
25. Beckham JC, Flood AM, Dennis MF, Calhoun PS. Ambulatory cardiovascular activity and hostility ratings in women with chronic posttraumatic stress disorder. Biol Psychiatry 2009;65:268-72
26. Miller TQ, Smith TW, Turner CW, Guijarro ML, Hallet AJ. A meta-analytic review of research on hostility and physical health. Psychol Bull 1996;119:322-48
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC: American Psychiatric Association, 1994
28. Rasmusson AM, Hauger RL, Morgan CA III, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) in combat-related posttraumatic stress disorder. Biol Psychiatry 2000;47:526-39
29. Rasmusson AM, Vasek J, Lipschitz D, Mustone ME, Vojvoda D, Shi Q, Gudmundsen G, Wolfe J, Morgan CA III, Charney DS. An increased capacity for adrenal DHEA release is associated negatively with avoidance symptoms and negative mood in women with PTSD. Neuropsychopharmacology 2004;29:1546-57 (Pubitemid 38982248)
30. Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney DS, Krystal J, Guidotti A. Decreased cerebrospinal fluid allopregnanolone levels in women with PTSD. Biol Psychiatry 2006;60:704-13
31. Gill J, Vythilingam M, Page GG. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J Trauma Stress 2008;21:530-9
32. Britton KT, Southerland S, Van Uden E, Kirby D, Rivier J, Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology 1997;132:6-13 (Pubitemid 27303733)
33. Britton KT, Akwa Y, Southerland S, Koob GF. Neuropeptide Y blocks the 'anxiogenic-like' behavioral action of corticotropin-releasing factor. Peptides 2000;21:37-44
34. Heilig M, Soderpalm B, Engel J, Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989;98:524-9 (Pubitemid 19193902)
35. Heilig M, McLeod S, Brot M, Heinrichs S, Menzaghi F, Koob G, Britton K. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993;8:357-63 (Pubitemid 23162961)
36. Kask A, Rago L, Harro J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur J Pharmacol 1996;317:R3-4
37. 1 receptor antagonist BIBP3226 in rats. NeuroReport 1997;8:3645-7
38. Howell OW, Silva S, Scharfman HE, Sosunov AA, Zaben M, Shatya A, McKhann G II, Herzog H, Laskowski A, Gray WP. Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol Dis 2007;26:174-88
39. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001;410:940-4
40. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, Virkkunen M, Mash DC, Lipsky RH, Hu XZ, Hodgkinson CA, Xu K, Buzas B, Yuan Q, Shen PH, Ferrell RE, Manuck SB, Brown SM, Hauger RL, Stohler CS, Zubieta JK, Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008;452:997-1001
41. Morgan CA, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry 2000;47:902-9 (Pubitemid 30243178)
42. Morgan CA III, Rasmusson AM, Wang S, Hoyt G, Hauger R, Hazlett G. Neuroeptide Y and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry 2002;52:136-42 (Pubitemid 34759984)
43. 2 antagonist yohimbine. Neuropsychopharmacology 1998;19:95-8
44. Yehuda R, Brand S, Yank RK. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD and coping. Biol Psychiatry 2005;59:660-3 (Pubitemid 43357961)
45. Antonijevic IA, Murck H, Bohlhalter S, Frieboes RM, Holsboer F, Steiger A. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 2000;39:1474-81 (Pubitemid 30249209)
46. Held K, Antonijevic I, Murck H, Kuenzel H, Steiger A. Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrine 2006;31:100-7 (Pubitemid 41668898)
47. Shih C-D, Chan JYH, Chan SHH. Tonic suppression of baroreceptor reflex response by endogenous neuropeptide Y at the nucleus tractus solitarius of the rat. Neurosci Lett 1992;148:169-72
48. Ergene E, Dunbar JC, Barraco RA. Visceroendocrine responses elicited by neuropeptide Y in the nucleus tractus solitarius. Brain Res Bull 1993;32:461-5 (Pubitemid 23251948)
49. Potter EK, Ulman LG. Neuropeptides in sympathetic nerves affect vagal regulation of the heart. NIPS 1994;9:174-7
50. Shine J, Potter EK, Biden T, Selbie LA, Herzog H. Neuropeptide Y and regulation of the cardiovascular system. J Hypertension 1994;12(Suppl. 10):S41-5
51. Ulman LG, Potter IK, McCloskey DI, Morris MJ. Post-exercise depression of baroreflex slowing of the heart in humans. Clin Physiol 1997;17:299-309
52. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann NY Acad Sci 1995;771:219-33
53. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Peptides 1998;75-76:231-8
54. Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. Can J Physiol Pharmacol 2003;81:177-85
55. Zukowska-Grojec Z. NeuropeptideY: an adrenergic cotransmitter, vasoconstrictor, and a nerve-derived vascular growth factor. Adv Pharmacol 1998;42:125-8
56. Yang L, Scott KA, Hyun J, Tamashiro KL, Tray N, Moran TH, Bi S. Role of dorsomedial hypothalamic neuropeptide Y in modulating food intake and energy balance. J Neurosci 2009;29:179-90
57. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol 1994;266:R1765-70
58. Kapio K, Kallio J, Pesonen U. Mitochondrial targeting signal in human neuropeptide Y gene. Biochem Biophys Res Commun 2005;337:633-40
59. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, Herzog H, Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007;13:803-11
60. Colmers W, Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. TINS 1994;17:373-9
61. Corder R, Castagne V, Rivet J-M, Mormede P, Gaillard RC. Central and peripheral effects of repeated stress and high NaCl diet on neuropeptide Y. Physiol Behav 1992;52:205-10
62. Morgan CA, Rasmusson AM, Winters B, Hauger RL, Hazlett G. Trauma exposure rather than PTSD is associated with reduced baseline plasma neuropeptide-Y levels. Biol Psychiatry 2003;54:1087-91
63. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolauuo A, Heninger GR, Charney DS. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:266-74
64. Jin H, Lanouette NM, Mudaliar S, Henry R, Folsom DP, Khandrika S, Glorioso DK, Jeste DV. Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome. J Clin Psychopharmacol 2009;29:210-15
65. Archelos J, Xiang J, Reinecke M, Lang R. Regulation of release and function of neuropeptides in the heart. J Cardiovasc Pharmacol 1987;12:S45-50
66. Dahlof P, Tarizzo V, Lundberg J, Dahlof C. Alpha- and beta-adrenoceptor-mediated effects on nerve stimulation-evoked release of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea pig. J Auton Nerv System 1991;35:199-210
67. Haass M, Cheng B, Richardt G, Lang R, Schomig A. Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn-Schmiedebergs Arch Pharmacol 1991;339:71-8 (Pubitemid 19074402)
68. Lundberg J, Rudehill A, Sollevi A. Pharmacological characterization of neuropeptide Y and noradrenaline mechanisms in sympathetic control of pig spleen. Eur J Pharmacol 1989;163:103-13
69. Pernow J. Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control. Acta Physiol Scand 1986;568:1-56
70. Pernow J, Lundberg J. Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha 2, NPY and angiotensin II receptors. Naunyn-Schmiedebergs Arch Pharmacol 1989;340:379-85
71. Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, Heinonen OJ, Uusitupa MI, Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine7 to proline7 polymorphism in the signal peptide of pre-proneuropeptide Y in humans. FASEB J 2001;15:1242-4
72. Nikisch G, Mathé AA. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry: J Assoc Eur Psychiatrists 2008;23:356-9
73. Uusitupa MI, Karvonen MK, Pesonen U, Koulu M. Neuropeptide Y: a novel link between the neuroendocrine system and cholesterol metabolism. Ann Med 1998;30:508-10
74. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001;159:145-51
75. van Rossum CT, Pijl H, Adan RA, Hoebee B, Seidell JC. Polymorphisms in the NPY and AGRP genes and body fatness in Dutch adults. Int J Obes 2006;30:1522-8 (Pubitemid 44470201)
76. Boscarino JA. Diseases among men 20 years after exposure to severe stress: implications for clinical research and medical care. Psychosomatic Med 1997;59:605-14
77. Boscarino JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. Psychosomatic Med 2008;70:668-76
78. Brass LM, Page WF. Stroke in former prisoners of war. J Stroke Cerebrovasc Dis 1996;6:72-8
79. Dobie DJ, Kivlahan DR, Maynard C, Bush KR, Davis TM, Bradley KA. Posttraumatic stress disorder in female veterans: association with self-reported health problems and functional impairment. Arch Intern Med 2004;164:394-400 (Pubitemid 38240703)
80. Brzezinski M. (unpublished findings) Reported at the annual meeting of the American Society of Anesthesiologists, October 17-21, New Orleans, 2009. See: www.asahq.org/news/2009AM-Brzezinski-FINAL.pdf (last checked 22 July 2010)
81. Uzunova V, Sheline Y, Davis J, Rasmusson A, Uzunova D, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95:3239-44 (Pubitemid 28135886)
82. A receptors. Prog Neurobiol 2003;71:67-80
83. Puia G, Mienville J-M, Matsumoto K, Takahata H, Watanabe H, Costa E, Guidotti A. On the putative physiological role of allopregnanolone on GABAA receptor function. Neuropharmacology 2003;44:49-55 (Pubitemid 36135841)
84. Mitchell SJ, Silver RA. Shunting inhibition modulates neuronal gain during synaptic excitation. Neuron 2003;38:433-45
85. Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABAA receptors. TINS 2004;27:569-75 (Pubitemid 39149827)
86. Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABAA receptors: modulating gain and maintaining the tone. TINS 2004;27:262-9 (Pubitemid 38529954)
87. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311-22
88. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, Nappi RE, Luisi S, Palumbo M, Purdy RH, Luisi M. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998;83:2099-103
89. Ghoumari AM, Ibanez C, El-Etr M, Leclerc P, Eychenne B, O'Malley BW, Baulieu EE, Schumacher M. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 2003;86:848-59
90. VanLandingham JW, Cekic M, Cutler S, Hoffman SW, Stein DG. Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci Lett 2007;425:94-8
91. Guidotti A, Dong E, Matsumoto K, Pinna G, Rasmusson AM, Costa E. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5α-dihydroprogesterone in psychiatric disorders. Brain Res Rev 2001;37:110-15
92. Pibiri F, Nelson M, Guidotti A, Costa E, Pinna G. Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: a model relevant for posttraumatic stress disorder. Proc Natl Acad Sci USA 2008;105:5567-72
93. Penning TM, Burczynski ME, Jez JM, Hung C-F, Lin H-K, Ma H, Moore M, Palackal N, Ratnam L. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-ketoreductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;35:67-77
94. Mitev YA, Darwish M, Wolf SS, Holsboer F, Almeida OF, Patchev VK. Gender differences in the regulation of 3 alpha-hydroxysteroid dehydrogenase in rat brain and sensitivity to neurosteroid-mediated stress protection. Neuroscience 2003;120:541-9
95. Morgan CA, Wang S, Mason J, Southwick SM, Fox P, Hazlett G, Charney DS, Greenfield G. Hormone profiles in humans experiencing military survival training. Biol Psychiatry 2000;47:891-901
96. Ebinger M, Sievers C, Ivan D, Schneider HJ, Stalla GK. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression? J Psychopharmacol 2009;23:841-53
97. Rasmusson AM, Vythilingam M, Morgan CA III. The neuroendocrinology of PTSD - new directions. CNS Spectrums 2003;8:651-67
98. Yehuda R. Current status of cortisol findings in post-traumatic stress disorder. Psychiatric Clin N Am 2002;25:341-68
99. Young EA, Breslau N. Cortisol and catecholamines in posttraumatic stress disorder: an epidemiologic community study. Arch Gen Psychiatry 2004;61:394-401 (Pubitemid 38451549)
100. Hou YT, Lin HK, Penning TM. Dexamethasone regulation of the rat 3α-hydroxysteroid/dihydrodiol dihydrogenase (3α-HSD/DD) gene. Mol Pharmacol 1998;53:459-66
101. Raison CL, Miller AH. When not enough is too much. The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003;160:1554-65
102. Charmandari E, Chrousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann NY Acad Sci 2006;1083:37-53
103. Livadas S, Dracopoulou M, Lazaropoulou C, Papassotiriou I, Sertedaki A, Angelopoulos GN, Chrousos GP, Dacou-Voutetakis C. A favorable metabolic and antiatherogenic profile in carriers of CYP21A2 gene mutations supports the theory of a survival advantage in this population. Hormone Res 2009;72:337-43
104. Witchel S, Lee P, Suda-Hartman S, Trucco M, Hoffman E. Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997;82:2097-101
105. Yehuda R, Bierer LM. Transgenerational transmission of cortisol and PTSD risk. Prog Brain Res 2008;167:121-35
106. Rosenfeld RS, Hellman L, Roffwarg H, Weitzman ED, Fukushima DK, Gallagher TF. Dehydroisoandrosterone is secreted episodically and synchronously with cortisol by normal man. J Clin Endocrinol 1971;33:87-92
107. Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol 2000;21:1-56
108. Morfin R, Starka L. Neurosteroid 7-hydroxylation products in the brain. Int Rev Neurobiol 2001;46:79-95
109. Balazs Z, Schweizer RA, Frey FJ, Rohner-Jeanrenaud F, Odermatt A. DHEA induces 11β-HSD2 by acting on CCAAT/enhancer-binding proteins. J Am Soc Nephrol 2008;19:92-101
110. Sondergaard HP, Hansson LO, Theorell T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: findings from a longitudinal study of refugees in Sweden. Psychother Psychosom 2002;71:298-303
111. Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, de Jongh R, Bosmans E. Elevated serum interleukin-6 (IL-6) receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999;45:833-9 (Pubitemid 29185473)
112. Miller RJ, Sutherland AG, Hutchison JD, Alexander DA. C-reactive protein and interleukin 6 receptor in post-traumatic stress disorder: a pilot study. Cytokine 2001;13:253-5
113. Schuld A, Mullington J, Freiss E, Hermann DM, Galanos C, Holsboer F, Pollmacher T. Changes in dehydroepiandrosterone (DHEA) and DHEA-sulfate plasma levels during experimental endotoxinemia in healthy volunteers. J Clin Endocrinol Metab 2000;85:4624-9 (Pubitemid 32157643)
114. Spivak B, Maayan R, Kotler M, Mester R, Gil-Ad I, Shtaif B, Weizman A. Elevated circulatory level of GABA A-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol Med 2000;30:1227-31
115. Yehuda R, Brand SR, Golier JA, Yang RK. Clinical correlates of DHEA associated with post-traumatic stress disorder. Acta Psychiatr Scand 2006;114:187-93 (Pubitemid 44186248)
116. Morgan CA III, Southwick S, Hazlett G, Rasmusson A, Hoyt G, Zimolo Z, Charney D. Relationships among plasma DHEA(S), cortisol, symptoms of dissociation and objective performance in humans exposed to acute stress. Arch Gen Psychiatry 2004;61:819-25
117. Morgan CA III, Rasmusson A, Pietrzak RH, Coric V, Southwick SM. Relationships among plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate, cortisol, symptoms of dissociation and objective performance in humans exposed to underwater navigation stress. Biol Psychiatry 2009;66:334-40
118. Kudielka BM, Hellhammer J, Hellhammer DH, Wolf OT, Pirke K-M, Varadi E. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a two-week DHEA treatment. J Clin Endocrinol Metab 1998;83:1756-61 (Pubitemid 28501054)
119. Deuster PA, Faraday MM, Chrousos GP, Poth MA. Effects of dehydroepiandrosterone and alprazolam on hypothalamic-pituitary responses to exercise. J Clin Endocrin Metab 2005;90:4777-83
120. Bertagna X, Escourolle H, Pinier JL, Coste J, Raux-Demay MC, Petal P. Administration of RU486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab 1994;78:375-80 (Pubitemid 24061756)
121. VanHaarst AD, Oitzl MS, Workel JO, DeKloet ER. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity. Endocrinology 1996;137:4935-43
122. Kroboth PD, Amico JA, Stone RA, Folan M, Frye RF, Kroboth FJ, Bigos KL, Fabian TJ, Linares AM, Pollock BG, Hakala C. Influence of DHEA administration on 24-hour cortisol concentrations. J Clin Psychopharmacol 2003;23:96-9 (Pubitemid 36167822)
123. Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertility Sterility 2003;80:1495-501 (Pubitemid 37532468)
124. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 2009;156:646-9
125. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, Simpson St, Clair L, Murphy JH, Haq N, Rubinow DR. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154-62 (Pubitemid 40189131)
126. Rabijewski M, Papierska L, Kozakowski J, Zgliczynski W. The relationship between androgens concentrations (testosterone and dehydroepiandrosterone sulfate) and metabolic syndrome in non-obese elderly men. Endokrynol Pol 2007;58:496-504
127. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292:2243-8
128. Hernandez-Morante JJ, Perez-de-Heredia F, Lujan JA, Zamora S, Garaulet M. Role of DHEA-S on body fat distribution: gender- and depot-specific stimulation of adipose tissue lipolysis. Steroids 2008;73:209-15
129. Navar D, Saulis D, Corll C, Svec F, Porter JR. Dehydroepiandrosterone (DHEA) blocks the increase in food intake caused by neuropeptide Y (NPY) in the Zucker rat. Nutr Neurosci 2006;9:225-32
130. Hernandez-Morante JJ, Milagro F, Gabaldon JA, Martinez JA, Zamora S, Garaulet M. Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur J Endocrinol 2006;155:593-600
131. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, Schutetz EG. PXR (NR112) splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 2004;199:251-65
132. Amato MC, Galluzzo A, Merlino S, Mattina A, Richiusa P, Criscimanna A, Giordano C. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome. Eur J Endocrinol 2006;155:859-65
133. Ding B, Kull B, Liu Z, Mottagui-Tabar S, Thonberg H, Gu HF, Brookes AJ, Grundemar L, Karlsson C, Hamsten A, Arner P, Ostenson CG, Efendic S, Monne M, von Heijne G, Eriksson P, Wahlestedt C. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul Peptides 2005;127:45-53
134. Nordman S, Ding B, Ostenson CG, Karvestedt L, Brismar K, Efendic S, Gu HF. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes 2005;113:282-7
135. Lavebratt C, Alpman A, Persson B, Arner P, Hoffstedt J. Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Int J Obesity 2006;30:453-9
136. Wang L, Rao F, Zhang K, Mahata M, Rodriguez-Flores JL, Fung MM, Waalen J, Cockburn MG, Hamilton BA, Mahata SK, O'Connor DT. Neuropeptide Y1 receptor NPY1R. Discovery of naturally occurring human genetic variants governing gene expression in cella as well as pleiotropic effects on autonomic activity and blood pressure in vivo. J Am Coll Cardiol 2009;54:944-54
137. Michalkiewicz M, Zhao GQ, Jia Z, Michalkiewicz T, Racadio MJ. Central neuropeptide Y signaling ameliorates N(omega)-nitro-L-arginine methyl ester hypertension in the rat through a Y1 receptor mechanism. Hypertension 2005;45:780-5 (Pubitemid 40418381)
138. 2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogen Genomics 2005;15:143-9
139. Neumeister A, Drevets WC, Belfer I, Luckenbaugh DA, Henry S, Bonne O, Herscovitch P, Goldman D, Charney DS. Effects of a alpha 2C-adrenoreceptor gene polymorphism on neural responses to facial expressions in depression. Neuropsychopharmacology 2006;31:1750-6 (Pubitemid 44106706)
140. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 2003;118B:60-5
141. Oswald LM, McCaul M, Choi L, Yang X, Wand GS. Catechol-O- methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report. Biol Psychiatry 2004;55:102-5 (Pubitemid 38045440)
142. Baghai TC, Schule C, Zwanzger P, Minov C, Zill P, Ella R, Eser D, Oezer S, Bondy B, Rupprecht R. Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neurosci Lett 2002;328:299-303
143. Wust S, Van Rossum EF, Federenko IS, Koper JW, Kumsta R, Hellhammer DH. Common polymorphisms in the glucocorticoid receptor gene are associated with adrenocortical responses to psychosocial stress. J Clin Endocrinol Metab 2004;89:565-73 (Pubitemid 38269859)
144. Slawik M, Reisch N, Zwermann O, Maser-Gluth C, Stahl M, Klink A, Reincke M, Beuschlein F. Characterization of an adrenocorticotropin (ACTH) receptor promoter polymorphism leading to decreased adrenal responsiveness to ACTH. J Clin Endocrinol Metab 2004;89:3131-7 (Pubitemid 38951874)
145. Gonzalez-Gay MA, Hajeer AH, Garcia-Porrua C, Dababneh A, Amoli MM, Botana MA, Thomson W, Llorca J, Ollier WE. Corticotropin-releasing hormone promoter polymorphisms in patients with rheumatoid arthritis from northwest Spain. J Rheumatol 2003;30:913-17 (Pubitemid 36529607)
146. Smoller JW, Rosenbaum JF, Biederman J, Kennedy J, Dai D, Racette SR, Laird NM, Kagan J, Snidman N, Hirshfeld-Becker D, Tsuang MT, Sklar PB, Slaugenhaupt SA. Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition. Biol Psychiatry 2003;54:1376-81
147. Challis BG, Luan J, Keogh J, Wareham NJ, Farooqi IS, O'Rahilly S. Genetic variation in the corticotrophin-releasing factor receptors: identification of single-nucleotide polymorphisms and association studies with obesity in UK Caucasians. Int J Obes Relat Metab Disord 2004;28:442-6
148. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y,
149. Yehuda R, Cai G, Golier JA, Sarapas C, Galea S, Ising M, Rein T, Schmeidler J, Müller-Myhsok B, Holsboer F, Buxbaum JD. Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. Biol Psychiatry 2009;66:708-11
150. Seckl JR, Meaney MJ. Glucocorticoid 'programming' and PTSD risk. Ann NY Acad Sci 2006;1071:351-78
151. Rauch SA, Grunfeld TE, Yadin E, Cahill SP, Hembree E, Foa EB. Changes in reported physical health symptoms and social function with prolonged exposure therapy for chronic posttraumatic stress disorder. Depress Anxiety 2009;26:732-8
152. Galovski TE, Monson C, Bruce SE, Resick PA. Does cognitive-behavioral therapy for PTSD improve perceived health and sleep impairment? J Trauma Stress 2009;22:197-204
153. Nishith P, Nixon RD, Resick PA. Resolution of trauma-related guilt following treatment of PTSD in female rape victims: a result of cognitive processing therapy targeting comorbid depression? J Affective Dis 2005;86:259-65
154. Kimerling R. An investigation of sex differences in nonpsychiatric morbidity associated with posttraumatic stress disorder. J Am Med Womens Assoc 2004;59:43-7
155. Otis JD, Keane TM, Kerns RD. An examination of the relationship between chronic pain and post-traumatic stress disorder. J Rehab Res Development 2003;40:397-405
156. Otis JD, Keane TM, Kerns RD, Monson C, Scioli E. The development of an integrated treatment for veterans with comorbid chronic pain and posttraumatic stress disorder. Pain Med 2009;10:1300-11
157. Schuebel K, Chen W, Cope L, Glockner SC, Xuzuki H, Yi J-M, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, Van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, Ahuja N, Herman JG, Baylin SB. Comparing the DNA hypermethalome with gene mutations in colorectal cancer. PLoS Genet 2007;3:e157
158. Goldstein LE, Rasmusson AM, Bunney BS, Roth RH. Role of the amygdala in the coordination of behavioral, neuroendocrine and prefrontal cortical monoamine responses to psychological stress in the rat. J Neurosci 1996;16:4787-98
159. Southwick SM, Rasmusson AM, Barron J, Arnsten A. Neurobiological and neurocognitive alterations in PTSD: a focus on norepinephrine, serotonin, and the HPA axis. In: Vasterling J, Brewin C, eds. Neuropsychology of PTSD. New York: Guilford Publications, 2005:27-58
160. Arnsten AF. Stress signaling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009;10:410-22
161. Cohen BE, Marmar C, Li R, Bertenthal D, Seal KH. Association of cardiovascular risk factors with mental health diagnoses in Iraq and Afghanistan war veterans using VA health care. JAMA 2009;302:489-92